But initially at least Canada was seen as an additional complication to completion of the TPP, a «difficult» negotiating partner that brought its own
baggage (such as a
less than robust IPR regime, a traditional antipathy to the interests of the
brand - name pharmaceutical manufacturers, a penchant for protecting so - called «cultural industries», and other trade issues that did not align with US interests) that might have resonated with some of the other TPP countries.